摘要
目的:从制剂稳定性角度对替罗非班致血小板减少不良反应的机制提出新的假说。方法:对接受替罗非班治疗的血小板减少症患者监测大血小板比率,结合中国专利数据库中关于替罗非班注射剂制剂稳定性数据进行分析,探讨两者的相关性。结果:替罗非班所致血小板减少与其存储过程中不溶性微粒的增加可能存在相关性。结论:替罗非班用药过程中应严格按说明书要求,在规定的时间点监测血小板计数、血红蛋白和血细胞比容。医院药剂科应针对其保质期短的特点,在流通和使用环节加强药品质量管理。
Objective: To put forward a new hypothesis of tirofiban-induced thrombocytopenia in the perspective of formu- lation stability. Methods: The ratio of large platelet in patients with tirofiban-induced thrombocytopenia was detected, and then analyzed on the basis of tirofiban injection stability data retrieved from China Patent Database. Results: Thrombocytopenia might be correlated with the increasing amount of insoluble particles in tirofiban injection during storage. Conclusion:The count of platelet, hemoglobin and hematocrit must be closely monitored when tirofiban injection is administered. The pharmacy department of the hospital should strengthen the quality control of tirofiban injection in the circulation and utilization procedures.
出处
《药学服务与研究》
CAS
2015年第5期361-365,共5页
Pharmaceutical Care and Research